Moleculin Biotech (MBRX) Income from Continuing Operations (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Income from Continuing Operations of 7574000.0 for Q4 2025, down 13.35% year-over-year from 8740840.76 in Q4 2024, and down 27.38% quarter-over-quarter from 5946000.0 in Q3 2025.
Moleculin Biotech (MBRX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Moleculin Biotech's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 7574000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 13.35% year-over-year to 7574000.0; the TTM figure through Dec 2025 stood at 25261000.0 (up 5.69% YoY), while the FY2025 annual figure was 68803000.0, down 5.46% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 7574000.0, down from 5946000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5240000.0 in Q4 2021, with the low at 9105000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 6565500.0 (2023), against an average of 6784300.0.
- The sharpest annual moves came in 2021 and 2023: Income from Continuing Operations tumbled 98.56% in 2021, then surged 34.31% in 2023.
- Moleculin Biotech's Income from Continuing Operations stood at 5240000.0 in 2021, then sank by 35.23% to 7086000.0 in 2022, then dropped by 26.22% to 8944000.0 in 2023, then increased by 25.29% to 6682000.0 in 2024, then declined by 13.35% to 7574000.0 in 2025.
- Business Quant data shows MBRX's Income from Continuing Operations at 7574000.0 in Q4 2025, 5946000.0 in Q3 2025, and 5759000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | -7.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Mn |
| Dec 31, 2025 | -7.57 Mn |
| Sep 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -5.98 Mn |
| Dec 31, 2024 | -6.68 Mn |
| Sep 30, 2024 | -7.17 Mn |
| Jun 30, 2024 | -6.22 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -8.94 Mn |
| Sep 30, 2023 | -5.98 Mn |
| Jun 30, 2023 | -6.45 Mn |
| Mar 31, 2023 | -8.39 Mn |
| Dec 31, 2022 | -7.09 Mn |
| Sep 30, 2022 | -9.11 Mn |
| Jun 30, 2022 | -7.47 Mn |
| Mar 31, 2022 | -7.11 Mn |
| Dec 31, 2021 | -5.24 Mn |
| Sep 30, 2021 | -6.19 Mn |
| Jun 30, 2021 | -5.55 Mn |